MA5-23917

antibody from Invitrogen Antibodies

Targeting: FOLR1 FOLR, FRα

Western blot (Supportive data in Antibodypedia)

ELISA (Recommended by provider)

Immunocytochemistry (Supportive data in Antibodypedia)

Flow cytometry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

MA5-23917

Provider

Invitrogen Antibodies

Product name

Folate Receptor alpha Monoclonal Antibody (548908)

Antibody type

Monoclonal

Antigen

Recombinant full-length protein

Description

In direct ELISAs, no cross-reactivity with recombinant human FOLR2, 3 or 4 is observed. Reconstitute at 0.5 mg/mL in sterile PBS.

Reactivity

Human

Host

Mouse

Isotype

IgG

Antibody clone number

548908

Vial size

100 µg

Concentration

0.5 mg/mL

Storage

-20° C, Avoid Freeze/Thaw Cycles

References

Submitted references

Clinically translatable quantitative molecular photoacoustic imaging with liposome-encapsulated ICG J-aggregates.

Wood CA, Han S, Kim CS, Wen Y, Sampaio DRT, Harris JT, Homan KA, Swain JL, Emelianov SY, Sood AK, Cook JR, Sokolov KV, Bouchard RR
Nature communications 2021 Sep 13;12(1):5410

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis from lysates of human cortex tissue and HeLa human cervical epithelial carcinoma cell line. PVDF membrane was probed with 2 µg/mL of mouse Anti-human FOLR1 Monoclonal Antibody (Product # MA5-23917) followed by HRP-conjugated Anti-mouse IgG Secondary Antibody. A specific band was detected for FOLR1 at approximately 40 kDa (as indicated). This experiment was conducted under non-reducing conditions.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of Folate Receptor alpha in human cortex tissue and HeLa human cervical epithelial carcinoma cell line. Samples were incubated in Folate Receptor alpha monoclonal antibody (Product # MA5-23917) using a dilution of 2 µg/mL followed by a HRP-conjugated Anti-Mouse IgG secondary antibody. A specific band was detected for FOLR1 at approximately 40 kDa (as indicated). Use under non-reducing conditions only.

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunocytochemistry analysis of Folate Receptor alpha in immersion fixed MCF-7 human breast cancer cell line. Samples were incubated in Folate Receptor alpha monoclonal antibody (Product # MA5-23917) using a dilution of 10 µg/mL for 3 hours at room temperature followed by NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red) and counterstained with DAPI (blue).

Flow cytometry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Flow cytometric analysis of MCF-7 human breast cancer cell line was stained with mouse Anti-human FOLR1 Monoclonal Antibody (Product # MA5-23917, filled histogram) or isotype control antibodyopen histogram), followed by Phycoerythrin-conjugated Anti-mouse IgG Secondary Antibody.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Flow cytometry of Folate Receptor alpha in MCF‚7 human breast cancer cell line. Samples were incubated in Folate Receptor alpha monoclonal antibody (Product # MA5-23917) or isotype control antibody followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Knockdown validation by Flow cytometry of Folate Receptor alpha in FOLR1 knockout MCF-7 human breast cancer cell line. Samples were incubated in Folate Receptor alpha monoclonal antibody (Product # MA5-23917) followed by a anti-Mouse IgG PE-conjugated secondary antibody. Cell line was stained with monoclonal antibody or isotype control antibody. No staining in the FOLR1 knockout MCF-7 cell line was observed.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 6 In vivo PA imaging specificity of targeted FRalpha-PAtrace in orthotopic ovarian cancer model. Results for targeted FRalpha-PAtrace (red) and non-targeted RG-16-PAtrace (green). Representative a , d axial MRI and b , e 800 nm PA image of SKOV3 tumors with ROIs indicated by red/green ellipses. MRI volumes were used to establish the position and size of tumors in PA images for ROI placement. Representative PAtrace contrast enhancement (CE) images thru postinjection time-points of c targeted FRalpha-PAtrace and f non-targeted RG-16-PAtrace. g PA-based SO 2 estimates for liver (left), spleen (middle), tumor (right) ROIs show that SO 2 does not change significantly through time, indicating no substantial physiological changes occurred during imaging. h PAtrace CE in the liver (left) and spleen (middle) ROIs suggest no significant difference between FRalpha-PAtrace and RG-16-PAtrace liver or spleen accumulation. PAtrace CE in tumor ROIs (right) presents positive enhancement for both targeted and non-targeted PAtrace immediately postinjection, but with targeted enhancement significantly greater 30 min ( p = 0.017) and 60 min ( p = 0.044) postinjection. Error bars indicate mean +- SD across three independent subjects.